Skip to content

IBD and Cannabinoid Medicine

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A with one of their gastroenterologists on the subject. 

People suffering from IBD often have symptoms that can easily interfere with life’s daily activities.  Those symptoms include:

  • Abdominal cramps and pain
  • Diarrhea that may be bloody
  • Severe urgency to have a bowel movement
  • Fever
  • Weight loss
  • Loss of appetite
  • Iron deficiency anemia due to blood loss

With many states that allow medical marijuana including IBD in their ‘qualifying conditions’ list, patients have been able to use cannabinoid medicine in conjunction with their traditional treatment to find symptom relief.  Our data at Arfinn Med indicates that patients adding cannabinoid treatment to their regiment have seen an improvement in their symptoms, indicating a 3.9 out of 5.0 on our symptom relief scale.

A screenshot of a cell phone

Description automatically generated

If you are suffering from IBD and are interested in learning more about cannabinoid medicine, please reach out to your physician to discuss ways of incorporating it into your existing treatment. If your physician would like more information, please refer them to Arfinn Med and its EMR and data portal focusing on complimentary and alternative medicines (CAM).

Resources:

https://healthblog.uofmhealth.org/digestive-health/cannabis-for-treating-ibd-hope-or-hype

https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-syndrome#1

https://www.healthline.com/health/crohns-disease/facts-statistics-infographic#1

Stories you may be interested in

Customize Your Patient Notes with Arfinn Med

Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More

State Board of Health reviews timelines for establishing Mississippi medical marijuana program

JACKSON, Miss. (WLBT) – The blueprint for Mississippi’s medical marijuana program is Initiative 65 that voters approved in November. That contains detailed requirements and the clock is ticking to get it started. The State Board of Health met virtually Wednesday to discuss the groundwork of the medical marijuana program. “I do want to tell you…
Read More

Cannabis reduces blood pressure in older adults, according to Ben-Gurion University researchers

Beer-Sheva, Israel…February 8, 2021 – A new discovery by researchers from Ben-Gurion University of the Negev (BGU) and its affiliated Soroka University Medical Center shows that medical cannabis may reduce blood pressure in older adults. The study, published in the European Journal of Internal Medicine, is the first of its kind to focus on the effect…
Read More

Arfinn Med March Updates

We are very happy to announce the release of several new functions within the Arfinn Med Platform.  Those include: * Text message updates from patients regarding their treatments * Templating for exam notes  * Updated analytics and dosing reports * Google calendar and Calendly integrations to schedule appointments. Please view the video below for more…
Read More

PTSD and Cannabis

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event.  That can include events such as  natural disasters, war/combat, a serious accident, or personal assault, among others.  People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.